Menu
Back to Journals » Cancer Management and Research » Volume 14
Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]
Authors Tong III J , Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng III L
Received 27 April 2022
Accepted for publication 27 April 2022
Published 5 May 2022 Volume 2022:14 Pages 1653—1654
Tong III J, Mao Y, Yang Z, et al. Cancer Manag Res. 2021;13:4041–4053.
The authors have advised due to an error at the time of figure assembly, Figure 2D on page 4048 is incorrect. The correct Figure 2 is shown in Download Article:
The authors apologize for this error and advise it does not affect the results of the paper.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.